• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>Progenics Pharmaceuticals

Progenics Pharmaceuticals

  1. All
  2. Morningstar Articles
  3. 3rd Party
  1. These stocks are down at least 20% in 2017 but Wall Street loves them anyway

    These stocks are down at least 20% in 2017 but Wall Street loves them anyway

  2. UPDATE: These stocks are down at least 20% in 2017 but Wall Street loves them anyway

    UPDATE: These stocks are down at least 20% in 2017 but Wall Street loves them anyway

  3. It’s Never Too Early: Roth 401(k)s and Other Fun Stuff

    Progenics Pharmaceuticals PGNX announced on March 6 that it would backtrack and reformulate the oral version opioid bowel dysfunction drug MNTX to make it more effective. If successful, the firm could file for its approval in late 2009. Our fair value estimate remains unchanged, as we'd already ...

1

©2017 Morningstar Advisor. All right reserved.